Matthew T Plavan's Net Worth
$629 Thousand
Who is Matthew T Plavan?
Matthew T Plavan does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include CESCA THERAPEUTICS INC., Arcadia Biosciences, Inc., and Origin Materials, Inc..
SEC CIK
Matthew T Plavan's CIK is 0001326765
Past Insider Trading and Trends
2019 was Matthew T Plavan's most active year for acquiring shares with 19 total transactions. Matthew T Plavan's most active month to acquire stocks was the month of July. 2014 was Matthew T Plavan's most active year for disposing of shares, totalling 3 transactions. Matthew T Plavan's most active month to dispose stocks was the month of May. 2011 saw Matthew T Plavan paying a total of $67,500.00 for 155,000 shares, this is the most they've acquired in one year. In 2014 Matthew T Plavan cashed out on 35,648 shares for a total of $42,557.02, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
CESCA THERAPEUTICS INC. (THMO) Snapshot price: $0.805
Former CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -6.58% | -17.27K |
$0.68 | -$11,788.31 | 245.07K |
Sep 2
| |||
Form 4/A
| -6.28% | -26.66K |
$1.37 | -$29,555.21 | 397.57K |
Jun 1 - Jun 1
| |||
Form 4
| -8.31% | -23.77K |
$1.05 | -$24,953.25 | 262.34K |
Dec 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 19
| |||
Form 4
| -2.81% | -8.49K |
$1.39 | -$11,798.32 | 293.6K |
Jul 29
| |||
Form 4
| +219.93% | 210K |
—
|
—
| 305.49K |
Mar 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 30
| |||
Form 4
| +171.43% | 75K |
—
|
—
| 118.75K |
Jul 29
| |||
Form 4
| +218.18% | 30K |
$2.25 | $67,500.00 | 43.75K |
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 30
| |||
Form 4
| +37.50% | 15K |
$0.56 | $8,400.00 | 55K |
Jan 9
| |||
Form 4
| +300.00% | 30K |
$0.52 | $15,600.00 | 40K |
Nov 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 10
| |||
Form 4
|
∞
| 10K |
—
|
—
| 10K |
Apr 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Arcadia Biosciences, Inc. (RKDA) Snapshot price: $2.61
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +4.27% | 585 |
$3.16 | $1,848.60 | 14.29K |
Aug 3 - Jan 21
| |||
Form 4
| +5.38% | 700 |
$1.72 | $1,204.00 | 13.7K |
Feb 3
| |||
Form 4
| +8.33% | 1K |
$4.08 | $4,079.50 | 13K |
Nov 14
| |||
Form 4
| +20.00% | 2K |
$5.25 | $10,500.00 | 12K |
Sep 23
| |||
Form 4
| +25.00% | 2K |
$6.51 | $13,013.50 | 10K |
Sep 10
| |||
Form 4/A
|
∞
| 8K |
$8.73 | $69,860.00 | 8K |
Aug 26 - Aug 28
| |||
Form 4
|
∞
| 8K |
$8.73 | $69,860.00 | 8K |
Aug 26 - Aug 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Origin Materials, Inc. (ORGN) Snapshot price: $0.525
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +21.88% | 241.1K |
—
|
—
| 1.34M |
Dec 26
| |||
Form 4
|
∞
| 1.1M |
—
|
—
| 1.1M |
Oct 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||